Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Nelfinavir, a new protease inhibitor: Early clinical results
W. G. Powderly
, P. Tebas
Division of Infectious Diseases
Institute of Clinical and Translational Sciences (ICTS)
COVID-19 Researchers
Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Department of Medicine
Institute for Public Health
Global Health Center (GHC)
Research output
:
Contribution to journal
›
Review article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Nelfinavir, a new protease inhibitor: Early clinical results'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Protease Inhibitors
100%
Nelfinavir
100%
HIV Patients
40%
HIV-1 Protease
40%
Clinical Trials
20%
Human Immunodeficiency Virus Type 1 (HIV-1)
20%
Diarrhea
20%
Inhibitory Activity
20%
Activity in Vivo
20%
Protease
20%
Potent Inhibitor
20%
Plasma Parameters
20%
Limit of Detection
20%
Codon
20%
Lamivudine
20%
Combination Therapy
20%
Zidovudine
20%
CD4+ Lymphocytes
20%
Plasma RNA
20%
Protease Gene
20%
Excellent Activity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Proteinase Inhibitor
100%
Nelfinavir
100%
HIV
80%
Human Immunodeficiency Virus Proteinase
40%
Combination Therapy
20%
Clinical Trial
20%
Diarrhea
20%
Side Effect
20%
Proteinase
20%
Zidovudine
20%
Lamivudine
20%